ライフサイエンスコーパス: inhaled glucocorticoid

1 ng beta-agonists and medium-to-high doses of inhaled glucocorticoids.

2 okers, 42% used bronchodilators and 23% used inhaled glucocorticoids.

3 mine changes in lung function in response to inhaled glucocorticoids.

4 rmacogenetic determinants of the response to inhaled glucocorticoids.

5 uncontrolled disease despite treatment with inhaled glucocorticoids.

6 Early intervention with inhaled glucocorticoids achieves symptom control but doe

7 ents whose asthma is poorly controlled by an inhaled glucocorticoid alone.

8 sociation of single therapy with systemic or inhaled glucocorticoids and improved outcomes in either

9 thma and elevated eosinophil levels who used inhaled glucocorticoids and LABAs, dupilumab therapy, as

10 poorly controlled asthma despite the use of inhaled glucocorticoids and LABAs, the addition of tiotr

11 912 patients with asthma who were receiving inhaled glucocorticoids and LABAs, we compared the effec

12 t airflow obstruction despite treatment with inhaled glucocorticoids and long-acting beta-agonists (L

13 omalizumab despite reductions in the use of inhaled glucocorticoids and long-acting beta-agonists.

14 we examined the relation between the dose of inhaled glucocorticoids and the rate of bone loss in pre

15 ons was similar among those who discontinued inhaled glucocorticoids and those who continued glucocor

16 Inhaled glucocorticoids are not as effective as systemic

17 Daily inhaled glucocorticoids are recommended for young childr

18 Although inhaled glucocorticoids are the mainstays of asthma trea

19 Inhaled glucocorticoids are the most commonly used medic

20 Inhaled glucocorticoids are the preferred long-term cont

21 s compared with a doubling of the dose of an inhaled glucocorticoid, as assessed by measuring the mor

22 tive pulmonary disease but not asthma) to an inhaled glucocorticoid, as compared with a doubling of t

23 oderate or severe exacerbations while taking inhaled glucocorticoid-based triple maintenance therapy.

24 Inhaled glucocorticoids can also improve airflow and can

25 , data are reassuring, supporting the use of inhaled glucocorticoids during pregnancy.

26 LABAs at week 4 and to taper and discontinue inhaled glucocorticoids during weeks 6 through 9.

27 ily or the LABA salmeterol (50 mug) plus the inhaled glucocorticoid fluticasone (500 mug) twice daily

28 y), salmeterol (50 mug twice daily), and the inhaled glucocorticoid fluticasone propionate (500 mug t

29 g the LABA salmeterol in combination with an inhaled glucocorticoid, fluticasone propionate.

30 We estimated the associations between use of inhaled glucocorticoids for asthma treatment during preg

31 The use of inhaled glucocorticoids for persistent asthma causes a t

32 opium Bromide as an Alternative to Increased Inhaled Glucocorticoid in Patients Inadequately Controll

33 A larger daily dose of inhaled glucocorticoid in the first 2 years was associat

34 However, the benefit of inhaled glucocorticoids in addition to two long-acting b

35 ed significantly to our current knowledge of inhaled glucocorticoids in childhood asthma.

36 Treatment with inhaled glucocorticoids in combination with long-acting

37 th substantial decrements in the response to inhaled glucocorticoids in patients with asthma.

38 n attained height associated with the use of inhaled glucocorticoids in prepubertal children persiste

39 ndicate reduced lung function in response to inhaled glucocorticoids in subjects with the variant all

40 Inhaled glucocorticoids, in addition, might reduce exace

41 height 1 to 4 years after the initiation of inhaled glucocorticoids is thought not to decrease attai

42 Inhaled glucocorticoids lead to a dose-related loss of b

43 edicted value and were taking a mean dose of inhaled glucocorticoids of 580 mug per day; 80% were als

44 The effects of inhaled glucocorticoids on outcomes in these infants are

45 er a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or a long-acting muscarinic antag

46 t least 3% who used medium-dose to high-dose inhaled glucocorticoids plus long-acting beta-agonists (

47 compared with a doubling of the dose of the inhaled glucocorticoid (primary superiority comparison)

48 Whether long-term therapy with inhaled glucocorticoids reduces bone mass, as oral gluco

49 enotype accounting for about 6.6% of overall inhaled glucocorticoid response variability.

50 ry with persistent asthma who required daily inhaled glucocorticoid therapy and 1988 matched controls

51 t of BHR confirmed the beneficial effects of inhaled glucocorticoid therapy and allergen avoidance on

52 Although the Expert Panel had recommended inhaled glucocorticoid therapy as the preferred long-ter

53 The safety and efficacy of inhaled glucocorticoid therapy for asthma stimulated its

54 Lastly, the safety of inhaled glucocorticoid therapy was also evaluated in pre

55 Inhaled glucocorticoid therapy was associated with a dos

56 ies were published that investigated whether inhaled glucocorticoid therapy, if started soon after th

57 hma that was inadequately controlled despite inhaled glucocorticoid therapy.

58 d less glucocorticoid responsiveness despite inhaled glucocorticoid therapy.

59 ng beta-agonists and medium-to-high doses of inhaled glucocorticoids, those who received tezepelumab

60 When added to an inhaled glucocorticoid, tiotropium improved symptoms and

61 cal interest was the comparative efficacy of inhaled glucocorticoid to systemic glucocorticoids in th

62 used on the comparative clinical efficacy of inhaled glucocorticoids to leukotriene receptor antagoni

63 inophilic inflammation despite high doses of inhaled glucocorticoids to one of three study groups.

64 We measured inhaled glucocorticoid use by means of monthly diaries,

65 th fewer asthma exacerbations when LABAs and inhaled glucocorticoids were withdrawn, with improved lu

66 It is unknown whether the concomitant use of inhaled glucocorticoids with LABAs mitigates those risks

67 despite continuous treatment with high-dose inhaled glucocorticoids with or without oral glucocortic

68 ested the hypothesis that early therapy with inhaled glucocorticoids would decrease the frequency of